Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Axsome Therapeutics announces 2021 anticipated milestones » 07:15
05/10/21
05/10
07:15
05/10/21
07:15
AXSM

Axsome Therapeutics

$56.82 /

+0.48 (+0.85%)

Anticipated Milestones:…

Anticipated Milestones: Regulatory and Commercial: AXS-05 for MDD, PDUFA target action date August 22, 2021; AXS-07 for migraine, NDA submission 2Q 2021; AXS-05 for smoking cessation, FDA meeting 3Q 2021; AXS-05 for MDD, commercial launch, if approved 2H 2021. Clinical Trial Readouts: Phase 2 MERIT trial of AXS-05 in TRD, topline data 2H 2021. Clinical Trial Initiations: Phase 3 trial of AXS-12 in the treatment of narcolepsy early 3Q 2021.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$56.82 /

+0.48 (+0.85%)

AXSM Axsome Therapeutics
$56.82 /

+0.48 (+0.85%)

04/27/21 H.C. Wainwright
Axsome Therapeutics price target raised to $225 from $210 at H.C. Wainwright
03/02/21 Mizuho
Axsome Therapeutics price target lowered to $118 from $120 at Mizuho
01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
AXSM Axsome Therapeutics
$56.82 /

+0.48 (+0.85%)

AXSM Axsome Therapeutics
$56.82 /

+0.48 (+0.85%)

Hot Stocks
Axsome Therapeutics expects cash to fund operations into at least 2024 » 07:14
05/10/21
05/10
07:14
05/10/21
07:14
AXSM

Axsome Therapeutics

$56.82 /

+0.48 (+0.85%)

Axsome believes that its…

Axsome believes that its cash at March 31, 2021, along with the remaining committed capital from the $225 million term loan facility, is sufficient to fund anticipated operations, based on the current operating plan, which includes costs for the commercial launch of AXS-05 in MDD and AXS-07 in migraine, into at least 2024. Axsome expects that its operating expenses will increase year over year as we continue to build out the commercial function and further advance our pipeline.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$56.82 /

+0.48 (+0.85%)

AXSM Axsome Therapeutics
$56.82 /

+0.48 (+0.85%)

04/27/21 H.C. Wainwright
Axsome Therapeutics price target raised to $225 from $210 at H.C. Wainwright
03/02/21 Mizuho
Axsome Therapeutics price target lowered to $118 from $120 at Mizuho
01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
AXSM Axsome Therapeutics
$56.82 /

+0.48 (+0.85%)

AXSM Axsome Therapeutics
$56.82 /

+0.48 (+0.85%)

Earnings
Axsome Therapeutics reports Q1 EPS (78c), consensus (87c) » 07:14
05/10/21
05/10
07:14
05/10/21
07:14
AXSM

Axsome Therapeutics

$56.82 /

+0.48 (+0.85%)

"We continued to…

"We continued to make significant strides in the quarter toward becoming a premier biopharmaceutical company focused on delivering potentially life-changing medicines to people living with serious CNS conditions. We successfully filed our NDA for AXS-05 for the treatment of MDD with the FDA, which was granted Priority Review, and are on track to file our NDA for AXS-07 for the acute treatment of migraine this quarter," said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. "Pre-commercial activities are intensifying as planned to ensure launch readiness assuming FDA approval. The rest of our pipeline continues to progress with the anticipated initiation of the planned Phase 3 trial for AXS-12 for the treatment of narcolepsy mid-year."

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$56.82 /

+0.48 (+0.85%)

AXSM Axsome Therapeutics
$56.82 /

+0.48 (+0.85%)

04/27/21 H.C. Wainwright
Axsome Therapeutics price target raised to $225 from $210 at H.C. Wainwright
03/02/21 Mizuho
Axsome Therapeutics price target lowered to $118 from $120 at Mizuho
01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
AXSM Axsome Therapeutics
$56.82 /

+0.48 (+0.85%)

AXSM Axsome Therapeutics
$56.82 /

+0.48 (+0.85%)

Over a week ago
Recommendations
Axsome Therapeutics price target raised to $225 from $210 at H.C. Wainwright » 06:07
04/27/21
04/27
06:07
04/27/21
06:07
AXSM

Axsome Therapeutics

$58.79 /

+6.04 (+11.45%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Axsome Therapeutics to $225 from $210 and reiterates a Buy rating on the shares. The AXS-05 approval timeline is shorter than expected, Selvaraju tells investors in a research note.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$58.79 /

+6.04 (+11.45%)

AXSM Axsome Therapeutics
$58.79 /

+6.04 (+11.45%)

03/02/21 Mizuho
Axsome Therapeutics price target lowered to $118 from $120 at Mizuho
01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
12/15/20 Mizuho
Axsome Therapeutics initiated with a Buy at Mizuho
AXSM Axsome Therapeutics
$58.79 /

+6.04 (+11.45%)

AXSM Axsome Therapeutics
$58.79 /

+6.04 (+11.45%)

On The Fly
Fly Intel: Pre-market Movers » 08:58
04/26/21
04/26
08:58
04/26/21
08:58
SJ

Scienjoy

$9.65 /

+0.12 (+1.26%)

, AXSM

Axsome Therapeutics

$52.97 /

+ (+0.00%)

, IMNM

Immunome

$29.59 /

+0.04 (+0.14%)

, GRA

W.R. Grace

$64.21 /

+0.91 (+1.44%)

, CHKP

Check Point

$119.93 /

-0.04 (-0.03%)

, OTIS

Otis Worldwide

$71.22 /

+0.27 (+0.38%)

, LII

Lennox

$334.29 /

-0.74 (-0.22%)

, NYCB

New York Community Bancorp

$11.98 /

+0.28 (+2.39%)

, BOH

Bank of Hawaii

$90.94 /

+2.54 (+2.87%)

, FBC

Flagstar Bancorp

$45.42 /

+1.57 (+3.58%)

, PHG

Philips

$61.12 /

+0.37 (+0.61%)

, CBU

Community Bank System

$78.57 /

+2.41 (+3.16%)

, PFPT

Proofpoint

$131.70 /

+1.04 (+0.80%)

, QURE

uniQure

$32.25 /

-0.66 (-2.01%)

Check out this morning's…

ShowHide Related Items >><<
SJ Scienjoy
$9.65 /

+0.12 (+1.26%)

QURE uniQure
$32.25 /

-0.66 (-2.01%)

PHG Philips
$61.12 /

+0.37 (+0.61%)

PFPT Proofpoint
$131.70 /

+1.04 (+0.80%)

OTIS Otis Worldwide
$71.22 /

+0.27 (+0.38%)

NYCB New York Community Bancorp
$11.98 /

+0.28 (+2.39%)

LII Lennox
$334.29 /

-0.74 (-0.22%)

IMNM Immunome
$29.59 /

+0.04 (+0.14%)

GRA W.R. Grace
$64.21 /

+0.91 (+1.44%)

FBC Flagstar Bancorp
$45.42 /

+1.57 (+3.58%)

CHKP Check Point
$119.93 /

-0.04 (-0.03%)

AXSM Axsome Therapeutics
$52.97 /

+ (+0.00%)

SJ Scienjoy
$9.65 /

+0.12 (+1.26%)

AXSM Axsome Therapeutics
$52.97 /

+ (+0.00%)

03/02/21 Mizuho
Axsome Therapeutics price target lowered to $118 from $120 at Mizuho
01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
12/15/20 Mizuho
Axsome Therapeutics initiated with a Buy at Mizuho
IMNM Immunome
$29.59 /

+0.04 (+0.14%)

10/27/20 Chardan
Immunome initiated with a Buy at Chardan
10/26/20 Ladenburg
Immunome initiated with a Buy at Ladenburg
GRA W.R. Grace
$64.21 /

+0.91 (+1.44%)

04/15/21 Wells Fargo
W.R. Grace price target raised to $70 from $65 at Wells Fargo
03/15/21 Credit Suisse
W.R. Grace assumed with an Outperform at Credit Suisse
02/10/21 Credit Suisse
W.R. Grace price target raised to $69 from $57 at Credit Suisse
01/19/21 CL King
W.R. Grace price target raised to $70 from $67 at CL King
CHKP Check Point
$119.93 /

-0.04 (-0.03%)

04/09/21 Oppenheimer
Check Point downgraded to Perform from Outperform at Oppenheimer
04/09/21 Oppenheimer
Check Point downgraded to Perform from Outperform at Oppenheimer
03/31/21 OTR Global
Check Point downgraded to Mixed from Positive at OTR Global
03/15/21 Credit Suisse
Check Point assumed with a Neutral at Credit Suisse
OTIS Otis Worldwide
$71.22 /

+0.27 (+0.38%)

04/06/21 Barclays
Otis Worldwide price target raised to $66 from $62 at Barclays
03/29/21 HSBC
Otis Worldwide upgraded to Hold from Reduce at HSBC
03/29/21 HSBC
Otis Worldwide upgraded to Hold from Reduce at HSBC
03/16/21 Berenberg
Otis Worldwide initiated with a Buy at Berenberg
LII Lennox
$334.29 /

-0.74 (-0.22%)

04/13/21 Deutsche Bank
Lennox price target raised to $310 from $307 at Deutsche Bank
04/06/21 Barclays
Lennox price target raised to $315 from $300 at Barclays
03/29/21 Morgan Stanley
Lennox price target raised to $258 from $240 at Morgan Stanley
02/25/21 Credit Suisse
Lennox downgraded to Underperform from Neutral at Credit Suisse
NYCB New York Community Bancorp
$11.98 /

+0.28 (+2.39%)

04/09/21 Jefferies
New York Community Bancorp price target raised to $13 from $11 at Jefferies
03/29/21 B. Riley
New York Community price target raised to $16 from $15 at B. Riley
03/05/21 B. Riley
New York Community Bancorp price target raised to $15 from $14 at B. Riley
02/05/21
New York Community Bancorp cut to Neutral at UBS on waning NIM expansion
BOH Bank of Hawaii
$90.94 /

+2.54 (+2.87%)

06/10/20 Piper Sandler
Bank of Hawaii assumed with a Neutral at Piper Sandler
FBC Flagstar Bancorp
$45.42 /

+1.57 (+3.58%)

04/05/21 Cowen
Risk to mortgage servicers rises as CFPB proposes foreclosure policy, says Cowen
01/22/21 B. Riley
Flagstar Bancorp price target raised to $55 from $46 at B. Riley Securities
12/30/20 Raymond James
Flagstar Bancorp price target raised to $56 from $46 at Raymond James
12/17/20 Compass Point
Flagstar Bancorp price target raised to $50 from $44 at Compass Point
PHG Philips
$61.12 /

+0.37 (+0.61%)

03/23/21 Barclays
Philips price target raised to EUR 55 from EUR 54 at Barclays
03/18/21 JPMorgan
Philips price target raised to EUR 50.70 from EUR 44.90 at JPMorgan
03/18/21 JPMorgan
Philips upgraded to Overweight from Neutral at JPMorgan
01/26/21 Credit Suisse
Philips price target raised to EUR 45 from EUR 41 at Credit Suisse
CBU Community Bank System
$78.57 /

+2.41 (+3.16%)

06/01/20 Stephens
Community Bank System resumed with an Equal Weight at Stephens
PFPT Proofpoint
$131.70 /

+1.04 (+0.80%)

04/26/21 Summit Insights
Proofpoint upgraded to Buy from Hold at Summit Insights
02/01/21 Stephens
Proofpoint initiated with an Overweight at Stephens
01/27/21 Truist
Proofpoint price target raised to $155 from $135 at Truist
01/15/21 Northland
Mimecast price target lowered to $70 from $77 at Northland
QURE uniQure
$32.25 /

-0.66 (-2.01%)

04/26/21 Credit Suisse
uniQure assumed with an Outperform at Credit Suisse
04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Mizuho
uniQure upgraded to Buy on favorable risk/reward at Mizuho
04/01/21 Mizuho
uniQure upgraded to Buy from Neutral at Mizuho
QURE uniQure
$32.25 /

-0.66 (-2.01%)

PHG Philips
$61.12 /

+0.37 (+0.61%)

PFPT Proofpoint
$131.70 /

+1.04 (+0.80%)

OTIS Otis Worldwide
$71.22 /

+0.27 (+0.38%)

NYCB New York Community Bancorp
$11.98 /

+0.28 (+2.39%)

LII Lennox
$334.29 /

-0.74 (-0.22%)

IMNM Immunome
$29.59 /

+0.04 (+0.14%)

GRA W.R. Grace
$64.21 /

+0.91 (+1.44%)

FBC Flagstar Bancorp
$45.42 /

+1.57 (+3.58%)

CHKP Check Point
$119.93 /

-0.04 (-0.03%)

CBU Community Bank System
$78.57 /

+2.41 (+3.16%)

BOH Bank of Hawaii
$90.94 /

+2.54 (+2.87%)

AXSM Axsome Therapeutics
$52.97 /

+ (+0.00%)

  • 06
    Nov
  • 02
    Oct
  • 10
    Aug
PHG Philips
$61.12 /

+0.37 (+0.61%)

CHKP Check Point
$119.93 /

-0.04 (-0.03%)

SJ Scienjoy
$9.65 /

+0.12 (+1.26%)

QURE uniQure
$32.25 /

-0.66 (-2.01%)

PHG Philips
$61.12 /

+0.37 (+0.61%)

PFPT Proofpoint
$131.70 /

+1.04 (+0.80%)

OTIS Otis Worldwide
$71.22 /

+0.27 (+0.38%)

NYCB New York Community Bancorp
$11.98 /

+0.28 (+2.39%)

IMNM Immunome
$29.59 /

+0.04 (+0.14%)

GRA W.R. Grace
$64.21 /

+0.91 (+1.44%)

FBC Flagstar Bancorp
$45.42 /

+1.57 (+3.58%)

CHKP Check Point
$119.93 /

-0.04 (-0.03%)

AXSM Axsome Therapeutics
$52.97 /

+ (+0.00%)

Hot Stocks
Axsome Therapeutics says FDA accepts NDA for AXS-05 » 06:02
04/26/21
04/26
06:02
04/26/21
06:02
AXSM

Axsome Therapeutics

$52.97 /

+ (+0.00%)

Axsome Therapeutics…

Axsome Therapeutics announced that the U.S.FDA has accepted for filing the company's New Drug Application for AXS-05 for the treatment of major depressive disorder, and has granted the application Priority Review. AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. The FDA has set a Prescription Drug User Fee Act target action date for the AXS-05 NDA of August 22.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$52.97 /

+ (+0.00%)

AXSM Axsome Therapeutics
$52.97 /

+ (+0.00%)

03/02/21 Mizuho
Axsome Therapeutics price target lowered to $118 from $120 at Mizuho
01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
12/15/20 Mizuho
Axsome Therapeutics initiated with a Buy at Mizuho
AXSM Axsome Therapeutics
$52.97 /

+ (+0.00%)

AXSM Axsome Therapeutics
$52.97 /

+ (+0.00%)

Conference/Events
Cantor Fitzgerald biotech analyst to hold analyst/industry conference call » 10:25
04/13/21
04/13
10:25
04/13/21
10:25
AXSM

Axsome Therapeutics

$51.79 /

-0.05 (-0.10%)

Biotech Analyst Duncan…

Biotech Analyst Duncan along with Key Opinion Leader, Dr. Porsteinsson, Alzheimer's Disease Care Research Director at the University Of Rochester, discuss emerging therapies for psychiatric symptoms of Alzheimer's and other neurodegenerative diseases, including Axsome Therapeutics' AXS-05. on an Analyst/Industry conference call to be held on April 13 at 11 am.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$51.79 /

-0.05 (-0.10%)

AXSM Axsome Therapeutics
$51.79 /

-0.05 (-0.10%)

03/02/21 Mizuho
Axsome Therapeutics price target lowered to $118 from $120 at Mizuho
01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
12/15/20 Mizuho
Axsome Therapeutics initiated with a Buy at Mizuho
AXSM Axsome Therapeutics
$51.79 /

-0.05 (-0.10%)

AXSM Axsome Therapeutics
$51.79 /

-0.05 (-0.10%)

Conference/Events
Cantor Fitzgerald biotech analyst to hold analyst/industry conference call » 08:44
04/13/21
04/13
08:44
04/13/21
08:44
AXSM

Axsome Therapeutics

$51.78 /

-1.16 (-2.19%)

Biotech Analyst Duncan…

Biotech Analyst Duncan along with Key Opinion Leader, Dr. Porsteinsson, Alzheimer's Disease Care Research Director at the University Of Rochester, discuss emerging therapies for psychiatric symptoms of Alzheimer's and other neurodegenerative diseases, including Axsome Therapeutics' AXS-05. on an Analyst/Industry conference call to be held on April 13 at 11 am.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$51.78 /

-1.16 (-2.19%)

AXSM Axsome Therapeutics
$51.78 /

-1.16 (-2.19%)

03/02/21 Mizuho
Axsome Therapeutics price target lowered to $118 from $120 at Mizuho
01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
12/15/20 Mizuho
Axsome Therapeutics initiated with a Buy at Mizuho
AXSM Axsome Therapeutics
$51.78 /

-1.16 (-2.19%)

AXSM Axsome Therapeutics
$51.78 /

-1.16 (-2.19%)

Over a month ago
Recommendations
Axsome Therapeutics price target lowered to $118 from $120 at Mizuho » 06:49
03/02/21
03/02
06:49
03/02/21
06:49
AXSM

Axsome Therapeutics

$69.21 /

+1.66 (+2.46%)

Mizuho analyst Vamil…

Mizuho analyst Vamil Divan lowered the firm's price target on Axsome Therapeutics to $118 from $120 and keeps a Buy rating on the shares following the company's Q4 results. The analyst expects AXS-05 to obtain a Priority Review, and expects the stock to rise as investors come to appreciate AXS-05's potential.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$69.21 /

+1.66 (+2.46%)

AXSM Axsome Therapeutics
$69.21 /

+1.66 (+2.46%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
12/15/20 Mizuho
Axsome Therapeutics initiated with a Buy at Mizuho
12/03/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $161 from $131 at Cantor Fitzgerald
AXSM Axsome Therapeutics
$69.21 /

+1.66 (+2.46%)

AXSM Axsome Therapeutics
$69.21 /

+1.66 (+2.46%)

Conference/Events
Cowen to hold a virtual conference » 09:07
03/01/21
03/01
09:07
03/01/21
09:07
QGEN

Qiagen

$50.02 /

-0.33 (-0.66%)

, SLN

Silence Therapeutics

$28.01 /

+ (+0.00%)

, BIIB

Biogen

$272.68 /

-4.95 (-1.78%)

, AXSM

Axsome Therapeutics

$67.52 /

-1.04 (-1.52%)

, GBT

Global Blood Therapeutics

$42.60 /

-0.885 (-2.04%)

, OCUL

Ocular Therapeutix

$18.40 /

+0.27 (+1.49%)

, ACAD

Acadia Pharmaceuticals

$49.00 /

+1.605 (+3.39%)

, PACB

Pacific Biosciences

$30.57 /

-0.59 (-1.89%)

, ZTS

Zoetis

$155.41 /

-1.14 (-0.73%)

, QTNT

Quotient

$4.49 /

-0.06 (-1.32%)

, DVAX

Dynavax

$8.75 /

+0.595 (+7.30%)

, OTRK

Ontrak

$59.13 /

-3.3 (-5.29%)

, ARQT

Arcutis Biotherapeutics

$34.11 /

+0.01 (+0.03%)

, PFE

Pfizer

$33.49 /

-0.335 (-0.99%)

, BLFS

BioLife Solutions

$39.29 /

+0.07 (+0.18%)

, CHRS

Coherus Biosciences

$16.22 /

+0.97 (+6.36%)

, SAGE

Sage Therapeutics

$85.02 /

+1.45 (+1.74%)

, CERS

Cerus

$6.14 /

-0.325 (-5.03%)

, EXEL

Exelixis

$21.70 /

-0.26 (-1.18%)

, ALNY

Alnylam

$147.94 /

+1.4 (+0.96%)

41st Annual Healthcare…

41st Annual Healthcare Virtual Conference will be held on March 1-4 beginning at 9:10 am on March 1. Webcast Link

ShowHide Related Items >><<
ZTS Zoetis
$155.41 /

-1.14 (-0.73%)

SLN Silence Therapeutics
$28.01 /

+ (+0.00%)

SAGE Sage Therapeutics
$85.02 /

+1.45 (+1.74%)

QTNT Quotient
$4.49 /

-0.06 (-1.32%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

OTRK Ontrak
$59.13 /

-3.3 (-5.29%)

OCUL Ocular Therapeutix
$18.40 /

+0.27 (+1.49%)

GBT Global Blood Therapeutics
$42.60 /

-0.885 (-2.04%)

EXEL Exelixis
$21.70 /

-0.26 (-1.18%)

DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

CHRS Coherus Biosciences
$16.22 /

+0.97 (+6.36%)

CERS Cerus
$6.14 /

-0.325 (-5.03%)

BLFS BioLife Solutions
$39.29 /

+0.07 (+0.18%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

ALNY Alnylam
$147.94 /

+1.4 (+0.96%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
SLN Silence Therapeutics
$28.01 /

+ (+0.00%)

11/18/20 BTIG
Silence Therapeutics initiated with a Buy at BTIG
BIIB Biogen
$272.68 /

-4.95 (-1.78%)

02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
02/08/21 Citi
Expert sees Biogen aducanumab approval 50/50 at best, says Citi
02/04/21 SVB Leerink
Biogen price target lowered to $380 from $430 at SVB Leerink
02/04/21 Credit Suisse
Biogen price target lowered to $338 from $350 at Credit Suisse
AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Jefferies
Axsome Therapeutics initiated with a Buy at Jefferies
12/15/20 Mizuho
Axsome Therapeutics initiated with a Buy at Mizuho
12/03/20 Cantor Fitzgerald
Axsome Therapeutics price target raised to $161 from $131 at Cantor Fitzgerald
GBT Global Blood Therapeutics
$42.60 /

-0.885 (-2.04%)

02/25/21 William Blair
Global Blood Therapeutics downgraded to Market Perform at William Blair
01/27/21 Oppenheimer
Global Blood Therapeutics' MAA accepted ahead of schedule, says Oppenheimer
01/20/21 Piper Sandler
Global Blood downgraded to Neutral from Overweight at Piper Sandler
12/15/20 H.C. Wainwright
Global Blood Therapeutics assumed with a Buy at H.C. Wainwright
OCUL Ocular Therapeutix
$18.40 /

+0.27 (+1.49%)

02/12/21 Piper Sandler
Ocular Therapeutix to update on OTX-TKI's Phase I wAMD, says Piper Sandler
12/30/20 JMP Securities
Ocular Therapeutix price target raised to $30 from $20 at JMP Securities
12/28/20
Fly Intel: Top five analyst calls
12/28/20 H.C. Wainwright
Ocular Therapeutix downgraded to Neutral from Buy at H.C. Wainwright
ACAD Acadia Pharmaceuticals
$49.00 /

+1.605 (+3.39%)

02/25/21 Mizuho
Acadia price target raised to $70 from $69 at Mizuho
12/29/20 Cantor Fitzgerald
Acadia price target raised to $70 from $61 at Cantor Fitzgerald
12/15/20 Mizuho
Acadia initiated with a Buy at Mizuho
11/16/20 Raymond James
Acadia upgraded to Strong Buy from Outperform at Raymond James
PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

02/11/21 Cantor Fitzgerald
Pacific Biosciences price target raised to $62 from $45 at Cantor Fitzgerald
02/11/21 Piper Sandler
Pacific Biosciences upgraded to Overweight from Neutral at Piper Sandler
01/15/21 Piper Sandler
Pacific Biosciences price target raised to $20 from $12 at Piper Sandler
01/12/21 Cantor Fitzgerald
Pacific Biosciences price target raised to $45 from $25 at Cantor Fitzgerald
ZTS Zoetis
$155.41 /

-1.14 (-0.73%)

02/17/21 Credit Suisse
Zoetis price target raised to $203 from $197 at Credit Suisse
11/12/20 Truist
Zoetis price target raised to $170 from $160 at Truist
11/06/20 Barclays
Zoetis price target raised to $189 from $175 at Barclays
09/21/20 Atlantic Equities
Zoetis initiated with an Overweight at Atlantic Equities
QTNT Quotient
$4.49 /

-0.06 (-1.32%)

05/18/20 Cowen
Quotient partner update suggests progress on antibody front, says Cowen
DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

02/08/21 Evercore ISI
Dynavax had 'big vaccine update week,' says Evercore ISI
02/01/21 Cowen
Dynavax undervalued for potential of Heplisav and COVID vaccine, says Cowen
02/01/21 H.C. Wainwright
Dynavax price target raised to $15 from $14 at H.C. Wainwright
11/06/20 H.C. Wainwright
Dynavax price target raised to $14 from $12 at H.C. Wainwright
OTRK Ontrak
$59.13 /

-3.3 (-5.29%)

01/05/21 Benchmark
GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
01/04/21 B. Riley
Ontrak price target raised to $110 from $100 at B. Riley Securities
11/18/20 B. Riley
Ontrak initiated with a Buy at B. Riley Securities
10/02/20 Canaccord
Ontrak analysis points to significant upside for shares, says Canaccord
ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

02/02/21 Truist
Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
02/01/21 Cowen
Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
01/28/21 JonesTrading
Arcutis Biotherapeutics initiated with a Buy at JonesTrading
11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
PFE Pfizer
$33.49 /

-0.335 (-0.99%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
BLFS BioLife Solutions
$39.29 /

+0.07 (+0.18%)

12/28/20 Northland
BioLife Solutions price target raised to $55 from $35 at Northland
11/09/20 KeyBanc
BioLife Solutions initiated with an Overweight at KeyBanc
10/19/20 B. Riley
BioLife Solutions price target raised to $35.50 from $30 at B. Riley Securities
09/23/20 B. Riley
BioLife Solutions price target raised to $30 from $25.50 at B. Riley FBR
CHRS Coherus Biosciences
$16.22 /

+0.97 (+6.36%)

02/25/21 Citi
Coherus Biosciences price target lowered to $27 from $30 at Citi
02/25/21 H.C. Wainwright
Coherus Biosciences price target lowered to $29 from $33 at H.C. Wainwright
11/19/20 Mizuho
Coherus Biosciences price target lowered to $30 from $35 at Mizuho
08/21/20 Mizuho
Express Scripts exclusion does not impact Coherus, says Mizuho
SAGE Sage Therapeutics
$85.02 /

+1.45 (+1.74%)

02/26/21 Mizuho
Sage Therapeutics downgraded to Neutral from Buy at Mizuho
02/25/21 Oppenheimer
Sage Therapeutics price target raised to $102 from $90 at Oppenheimer
02/25/21 H.C. Wainwright
Sage Therapeutics price target raised to $86 from $74 at H.C. Wainwright
02/24/21 Stifel
Stifel cuts Sage target to $121, reiterates Buy after quarterly results
CERS Cerus
$6.14 /

-0.325 (-5.03%)

11/30/20 Cowen
Value proposition for Cerus' Intercept cryo 'clear,' says Cowen
10/07/20 BTIG
Cerus assumed with a Buy at BTIG
08/19/20 Stifel
Cerus story about platelets, not convalescent plasma, says Stifel
08/10/20 Cowen
Cerus multi-layered sales growth trajectory 'convincing,' says Cowen
EXEL Exelixis
$21.70 /

-0.26 (-1.18%)

02/15/21 Piper Sandler
Exelixis price target raised to $36 from $33 at Piper Sandler
01/25/21 Piper Sandler
Piper says Exelixis could have 'blockbuster opportunity' with XL102
01/22/21 Piper Sandler
Exelixis combo approval came a month ahead of PDUFA, says Piper Sandler
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
ALNY Alnylam
$147.94 /

+1.4 (+0.96%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
ZTS Zoetis
$155.41 /

-1.14 (-0.73%)

SAGE Sage Therapeutics
$85.02 /

+1.45 (+1.74%)

QTNT Quotient
$4.49 /

-0.06 (-1.32%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

OTRK Ontrak
$59.13 /

-3.3 (-5.29%)

OCUL Ocular Therapeutix
$18.40 /

+0.27 (+1.49%)

GBT Global Blood Therapeutics
$42.60 /

-0.885 (-2.04%)

EXEL Exelixis
$21.70 /

-0.26 (-1.18%)

DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

CHRS Coherus Biosciences
$16.22 /

+0.97 (+6.36%)

CERS Cerus
$6.14 /

-0.325 (-5.03%)

BLFS BioLife Solutions
$39.29 /

+0.07 (+0.18%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

ALNY Alnylam
$147.94 /

+1.4 (+0.96%)

ACAD Acadia Pharmaceuticals
$49.00 /

+1.605 (+3.39%)

  • 03
    Feb
  • 16
    Dec
  • 11
    Nov
  • 14
    Oct
  • 02
    Oct
  • 11
    Sep
  • 12
    Aug
  • 02
    Jul
  • 22
    May
  • 20
    May
ZTS Zoetis
$155.41 /

-1.14 (-0.73%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

ALNY Alnylam
$147.94 /

+1.4 (+0.96%)

SAGE Sage Therapeutics
$85.02 /

+1.45 (+1.74%)

QTNT Quotient
$4.49 /

-0.06 (-1.32%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

OCUL Ocular Therapeutix
$18.40 /

+0.27 (+1.49%)

GBT Global Blood Therapeutics
$42.60 /

-0.885 (-2.04%)

EXEL Exelixis
$21.70 /

-0.26 (-1.18%)

DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

BLFS BioLife Solutions
$39.29 /

+0.07 (+0.18%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

AXSM Axsome Therapeutics
$67.52 /

-1.04 (-1.52%)

ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

QGEN Qiagen
$50.02 /

-0.33 (-0.66%)

PFE Pfizer
$33.49 /

-0.335 (-0.99%)

PACB Pacific Biosciences
$30.57 /

-0.59 (-1.89%)

OTRK Ontrak
$59.13 /

-3.3 (-5.29%)

DVAX Dynavax
$8.75 /

+0.595 (+7.30%)

BIIB Biogen
$272.68 /

-4.95 (-1.78%)

ARQT Arcutis Biotherapeutics
$34.11 /

+0.01 (+0.03%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.